Prothena Current Ratio 2011-2022 | PRTA

Prothena current ratio from 2011 to 2022. Current ratio can be defined as a liquidity ratio that measures a company's ability to pay short-term obligations.
Prothena Current Ratio Historical Data
Date Current Assets Current Liabilities Current Ratio
2022-09-30 $0.53B $0.05B 10.37
2022-06-30 $0.52B $0.04B 13.00
2022-03-31 $0.56B $0.04B 15.22
2021-12-31 $0.59B $0.03B 17.48
2021-09-30 $0.61B $0.03B 20.81
2021-06-30 $0.41B $0.05B 7.74
2021-03-31 $0.35B $0.02B 15.02
2020-12-31 $0.30B $0.03B 11.58
2020-09-30 $0.32B $0.02B 14.75
2020-06-30 $0.34B $0.02B 18.40
2020-03-31 $0.36B $0.02B 21.05
2019-12-31 $0.38B $0.02B 21.36
2019-09-30 $0.41B $0.03B 12.88
2019-06-30 $0.42B $0.03B 14.95
2019-03-31 $0.42B $0.02B 27.85
2018-12-31 $0.43B $0.02B 28.90
2018-09-30 $0.46B $0.02B 19.34
2018-06-30 $0.49B $0.05B 10.71
2018-03-31 $0.54B $0.04B 15.11
2017-12-31 $0.43B $0.04B 11.41
2017-09-30 $0.47B $0.04B 11.95
2017-06-30 $0.51B $0.04B 12.92
2017-03-31 $0.51B $0.03B 15.27
2016-12-31 $0.39B $0.04B 9.53
2016-09-30 $0.42B $0.04B 11.26
2016-06-30 $0.45B $0.03B 13.47
2016-03-31 $0.48B $0.02B 20.75
2015-12-31 $0.38B $0.02B 16.99
2015-09-30 $0.39B $0.02B 21.21
2015-06-30 $0.41B $0.01B 30.19
2015-03-31 $0.28B $0.01B 29.80
2014-12-31 $0.30B $0.01B 24.85
2014-09-30 $0.31B $0.01B 30.97
2014-06-30 $0.31B $0.01B 27.14
2014-03-31 $0.20B $0.01B 22.27
2013-12-31 $0.18B $0.01B 24.07
2013-09-30 $0.10B $0.01B 13.34
2013-06-30 $0.11B $0.01B 12.51
2013-03-31 $0.12B $0.01B 23.75
2012-12-31 $0.13B $0.00B 72.16
2012-09-30 $0.00B 0.00
2012-06-30 $0.00B 0.00
2012-03-31 $0.00B 0.00
2011-12-31 $0.00B $0.01B 0.01
2010-12-31 $0.00B 0.00
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $2.659B $0.201B
Prothena Corp. plc, being a clinical-stage neuroscience company, focused on the development of novel therapeutic therapies for life-threatening diseases. Its wholly owned programs include birtamimab for the potential treatment of AL amyloidosis, PRX004 for the potential treatment of ATTR amyloidosis and a portfolio of programs for the potential treatment of Alzheimer's disease including PRX012 that targets A?.?Prothena is also developing candidates in collaboration with bigwigs like Roche and Bristol-Myers Squibb. These programs include prasinezumab, in collaboration with Roche for the potential treatment of Parkinson's disease and other related synucleinopathies, and programs that target tau, TDP-43 and an undisclosed target in collaboration with Bristol-Myers Squibb for the potential treatment of Alzheimer's disease, amyotrophic lateralsclerosis, etc. It sold PRX004 and the broader ATTR amyloidosis program to Novo Nordisk. It derives revenues from license, development & commercialization agreements.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $153.147B 9.34
GSK (GSK) United Kingdom $71.894B 8.95
Bio-Rad Laboratories (BIO.B) United States $12.069B 28.64
QIAGEN (QGEN) Netherlands $11.086B 18.92
Ginkgo Bioworks Holdings (DNA) United States $3.531B 0.00
Myovant Sciences (MYOV) United Kingdom $2.613B 0.00
Arcus Biosciences (RCUS) United States $1.618B 24.29
Biohaven (BHVN) United States $1.266B 0.00
Emergent Biosolutions (EBS) United States $0.645B 5.07
ADC Therapeutics SA (ADCT) Switzerland $0.378B 0.00
Ambrx Biopharma (AMAM) United States $0.078B 0.00
Enzo Biochem (ENZ) United States $0.067B 0.00
SQZ Biotechnologies (SQZ) United States $0.024B 0.00
Gelesis Holdings (GLS) United States $0.022B 0.00